This site is intended for healthcare professionals

Specialty hub

Neurology (CNS) and Pain

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Neurology (CNS) and Pain.

Read time: 5 mins

Last updated: 7th Oct 2021

Welcome:

Sign in/Register

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Neurology is the branch of medicine that deals with conditions and diseases involving the central nervous system (brain and spinal cord) and the peripheral nervous systems (autonomic and somatic), including their coverings, blood vessels, and all effector tissue such as muscle.

Learning Zones

Multiple Sclerosis (MS) Learning Zone

Multiple Sclerosis (MS) Learning Zone

250 mins

Major depressive disorder and treatment-resistant depression

Learning Zone Homepage

Major depressive disorder and treatment-resistant depression

195 mins

Innovations in MS care to improve individual disease management

Innovations in MS care to improve individual disease management

145 mins

Anticoagulation Therapy for Stroke Prevention

Learning Zone Homepage

Anticoagulation Therapy for Stroke Prevention

500 mins

One Neuroscience and Pain Learning Zone

Learning Zone Homepage

One Neuroscience and Pain Learning Zone

830 mins

Neurology encompasses over 5000 neurological diseases and relies on insights from fields such as neuroscience. This medical speciality deals with dementia including Alzheimer’s disease, Parkinson’s disease, neuromuscular disorders including spinal muscular atrophy and pain management as a sub-speciality.

Diseases in this section

Attention Deficit Hyperactivity Disorder (ADHD)

Containing relevant Learning Zones, guidelines, trials and news.

Dementia

Containing relevant Learning Zones, guidelines, trials and news.

Depression

Containing relevant Learning Zones, guidelines, trials and news.

Epilepsy

Containing relevant Learning Zones, guidelines, trials and news.

Neuromuscular Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Pain

Containing relevant Learning Zones, guidelines, trials and news.

Parkinson's Disease

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

Sage Therapeutics + Biogen plan to submit an NDA for zuranolone.

Sage Therapeutics and Biogen announced their plan to submit a New Drug Application (NDA) to the n FDA for zuranolone, an investigational two-week, once-daily therapeutic in the second half of 2022.

1 mins

Top-line results from AP 013 phase III trial of Ampion in adult patients with severe osteoarthritis of the knee | medthority.com

Ampio Pharmaceuticals announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study evaluating the efficacy of an intra-articular (IA) injection of Ampion in adults with pain due to severe osteoarthritis of the knee (OAK) .

1 min

Phase III ULTIMATE I & II trials of TG 1101 shows improvement for multiple sclerosis.- TG Therapeutics

TG Therapeutics announced data presentations, including additional analyses from two global, active-controlled, Phase III studies, called ULTIMATE I & II, evaluating TG 1101 (ublituximab) compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS).

1 min

See all news

Related Drugs

Amitriptyline Hydrochloride 50 mg Film-Coated Tablets

Amitriptyline Hydrochloride 50 mg Film-Coated Tablets

18 mins

Amitriptyline Hydrochloride 25 mg Film-Coated Tablets

Amitriptyline Hydrochloride 25 mg Film-Coated Tablets

18 mins

Amitriptyline Hydrochloride 10 mg Film-Coated Tablets

Amitriptyline Hydrochloride 10 mg Film-Coated Tablets

18 mins

Galantamine 4mg/ml Oral Solution

Galantamine 4mg/ml Oral Solution

17 mins

Fycompa film-coated tablets (Northern Ireland)

Fycompa film-coated tablets (Northern Ireland)

38 mins

Fycompa 0.5mg/ml oral suspension (Northern Ireland)

Fycompa 0.5mg/ml oral suspension (Northern Ireland)

37 mins

Atomoxetine 40mg Capsules

Atomoxetine 40mg Capsules

29 mins

Atomoxetine 18 mg hard capsules

Atomoxetine 18 mg hard capsules

29 mins

Atomoxetine 10mg Capsules

Atomoxetine 10mg Capsules

29 mins

Amantadine Syrup 50mg

Amantadine Syrup 50mg

13 mins

Amantadine hydrochloride 100mg capsules

Amantadine hydrochloride 100mg capsules

10 mins

Alzest 13.3 mg/24 h Transdermal Patch

Alzest 13.3 mg/24 h Transdermal Patch

26 mins

Altridexamol 1000 mg Effervescent Tablets

Altridexamol 1000 mg Effervescent Tablets

8 mins

Pizotifen 1.5mg Tablets.

Pizotifen 1.5mg Tablets.

5 mins

Pizotifen 0.5mg Tablets

Pizotifen 0.5mg Tablets

5 mins

Related Journals

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression

1 mins

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression

1 mins

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

Vagus Nerve Stimulation For Treatment Resistant Depression: Case Series Of Six Patients - Retrospective Efficacy And Safety Observation After One Year Follow Up

1 mins

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

1 mins

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response

1 mins

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder

1 mins

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial

1 mins

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

1 mins

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study

1 mins

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression

1 mins

Related Guidelines

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

These recommendations were designed to ensure safety for patients with major depressive disorder (MDD) and to aid monitoring and management of adverse effects during treatment with approved antidepressant medications. The recommendations aim to inform prescribers about both the risks associated with these treatments and approaches for mitigating such risks.

1 mins

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use.

1 min

Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

Background: Clear guidance for successive antidepressant pharmacological treatments for non-responders in major depression is not well established.

1 min

See all guidelines

Related Clinical Trials

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

Minocycline as Adjunctive Treatment for Treatment Resistant Depression (MINDEP2)

2 mins

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

1 mins

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) (ELEKT-D)

1 mins

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

1 mins

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

1 mins

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

1 mins

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive D

1 mins

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (TRANSFORM-3)

2 mins

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis (TOWER)

3 mins

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

Identification of a Biomarker Predictive of Evolution of Parkinson Disease (GLIAPARK)

3 mins

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

3 mins

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults (GWPCARE3)

4 mins

Related Events

EAN Congress 2022

EAN Congress 2022

1 mins

Pain Week Conference 2021

Pain Week Conference 2021

1 mins

European Paediatric Neurology Society (EPNS) Congress 2022

1 mins

International Conference on Psychology (ICP) 2022

International Conference on Psychology (ICP) 2022

1 mins

Novartis sponsored satellite symposium at the 7th Congress of the European Academy of Neurology

Novartis sponsored satellite symposium at the 7th Congress of the European Academy of Neurology

1 mins

ECTRIMS 2021: Treating-to-target in multiple sclerosis

ECTRIMS 2021: Treating-to-target in multiple sclerosis

1 mins

39th International Congress of Psychology

39th International Congress of Psychology

1 mins

34th ECNP Congress

34th ECNP Congress

1 mins

Your peers are looking at...

Azurity Pharma acquires Arbor Pharma

Azurity Pharma acquires Arbor Pharma

1 mins

FDA approves Susvimo for age-related macular degeneration.- Genentech/Roche

FDA approves Susvimo for age-related macular degeneration.- Genentech/Roche

1 mins

Pepaxto withdrawn from market in US.- Oncopeptides

Pepaxto withdrawn from market in US.- Oncopeptides

1 mins

FDA issues Emergency Use Authorization for a booster dose of the JNJ 78436735 COVID 19 vaccine for adults aged 18 and older.- Johnson & Johnson

FDA issues Emergency Use Authorization for a booster dose of the JNJ 78436735 COVID 19 vaccine for adults aged 18 and older.- Johnson & Johnson

1 mins

FDA approves Ventana PD-L1 (SP263) assay for non-small cell lung cancer detection.- Roche

FDA approves Ventana PD-L1 (SP263) assay for non-small cell lung cancer detection.- Roche

1 mins

Phase III ECZTRA 6 trial of Adtralza meets its primary endpoints at 16 weeks for atopic dermatitis.- LEO Pharma

Phase III ECZTRA 6 trial of Adtralza meets its primary endpoints at 16 weeks for atopic dermatitis.- LEO Pharma

1 mins

Phase III SOLSTICE trial of Lonsurf fails to meet primary endpoint in colorectal cancer.- Servier

Phase III SOLSTICE trial of Lonsurf fails to meet primary endpoint in colorectal cancer.- Servier

1 mins

EU approves Keytruda plus chemo for metastatic triple-negative breast cancer.- Merck Inc

EU approves Keytruda plus chemo for metastatic triple-negative breast cancer.- Merck Inc

1 mins

Two phase III studies of Xiaflex show efficacy in Peyronie's disease.- Endo International

Two phase III studies of Xiaflex show efficacy in Peyronie's disease.- Endo International

1 mins

Baxter and bioMérieux announce CE Mark for NEPHROCLEAR CCL14 test to predict persistent severe acute kidney injury.

Baxter and bioMérieux announce CE Mark for NEPHROCLEAR CCL14 test to predict persistent severe acute kidney injury.

1 mins